RxDoctor Payments DataLook up a doctor →

Margarita Bruno-Padilla, MD

Hematology & Oncology · San Juan, PRNPI 1639119357

Payments from drug & device makers

$20,236in general payments, 2019–2025

Across 856 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • PBG Puerto Rico LLC$1K
  • Genentech USA, Inc.$1K
  • Johnson & Johnson$1K
  • plus $11K from 48 others

What the payments were for

  • Speaking & faculty fees$1,1256%
  • Food & beverage$18,37291%
  • Education$7394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,236 in reported general payments places this provider in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,259
Medicare patients
37
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib36$576,212
RevlimidLenalidomide20$389,192
VerzenioAbemaciclib17$273,421
VenclextaVenetoclax12$184,494
XareltoRivaroxaban19$10,975
Anastrozole416$10,188
Exemestane80$8,200
SynthroidLevothyroxine Sodium35$2,168
Letrozole82$1,412
Tamoxifen Citrate14$439
Gabapentin21$286
Famotidine35$257
Pantoprazole Sodium17$212
Dexamethasone18$212
Alendronate Sodium11$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$529$576,21236 claims
Bristol Myers SquibbRevlimid$125$389,19220 claims
AbbVieVenclexta, Synthroid$1,136$186,66247 claims
Johnson & JohnsonXarelto$1,180$10,97519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →